Beyond Medication: Lifestyle Interventions as a Pillar of Breast Cancer Risk Reduction with Douglas Marks, MD

·17 min·1 clip

Dr. Douglas Marks explains why lifestyle changes, not just drugs, are central to reducing breast cancer risk.

The episode begins with host Ella Holman introducing Dr. Douglas Marks, who is the medical director at NYU Langone Long Island Cancer Clinical Trials Office and an associate professor. Dr. Marks explains his interest in lifestyle interventions as a complement to traditional drug-based cancer treatments. He outlines the strongest evidence for reducing breast cancer risk, citing the Women's Health Initiative study that supports low-fat, plant-based diets and moderate physical exercise at least four times a week. Dr. Marks then addresses underappreciated interventions, focusing on alcohol consumption and advising a shift from daily drinking to special occasion intake. He highlights evidence gaps in the field, including the lack of biomarkers to measure intervention effectiveness and the underrepresentation of young women and minority communities in research. The conversation turns to health disparities, with Dr. Marks noting that socioeconomic factors and food deserts limit access to lifestyle interventions. He suggests policy changes like insurance subsidies and physician incentives to expand access. When asked about ownership of lifestyle counseling, Dr. Marks advocates for a shared responsibility between oncologists and primary care providers. Looking to the future, he expresses excitement about GLP drugs for weight loss and wearable technologies like Fitbits and Apple Watches, which could use AI to track patient progress. Dr. Marks concludes by emphasizing the need for a greater focus on primary prevention rather than reactive approaches after a cancer diagnosis.

As heard by us

A careful look at lifestyle, evidence gaps, and underrepresented populations in breast cancer prevention research.

Managed Care Cast uses a practical question, how lifestyle fits into breast cancer risk reduction, to open a more careful discussion about evidence gaps, representation, and newer weight-changing agents. Ella Holman speaks with Dr.

Read the full review in PlayNext →

Why you'd press play

You want a grounded pass on where lifestyle fits into breast cancer risk reduction, especially now that GLP drugs are raising new BMI-and-risk questions.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Managed Care Cast